Therefore, it is necessary to incorporate more effective biological indicators screened by whole exome sequencing or RNA-seq to further improve and enhance predictive ability and provide individual precision treatment for HER2-positibve breast cancer. This evidence concerns the gene ERBB2 and breast cancer.